The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 24, 2015

Filed:

Dec. 19, 2012
Applicants:

Development Center for Biotechnology, New Taipei, TW;

Dcb-usa Llc, Wilmington, New Castle, DE (US);

Inventors:

Yu-Shen Hsu, New Taipei, TW;

Show-Shan Sheu, New Taipei, TW;

Ming-I Chang, New Taipei, TW;

Ming-Chuan Chang, New Taipei, TW;

Ta-Tung Yuan, New Taipei, TW;

Assignees:

Development Center for Biotechnology, New Taipei, TW;

DCB-USA LLC, Wilmington, New Castle, DE (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 38/00 (2006.01); A61K 38/04 (2006.01); C07K 5/00 (2006.01); C07K 7/00 (2006.01); C07K 16/00 (2006.01); C07K 17/00 (2006.01); C12P 21/08 (2006.01); A61K 38/10 (2006.01); A61K 38/16 (2006.01); A61K 38/08 (2006.01); C07K 16/46 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C07K 16/468 (2013.01); C07K 7/06 (2013.01); C07K 7/08 (2013.01); C07K 16/2809 (2013.01); C07K 16/2887 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/732 (2013.01); C07K 2317/74 (2013.01); C07K 2317/94 (2013.01);
Abstract

This invention relates to bispecific antibodies having combinations of linker and hinge sequences to create linker-hinge interface domains with biological significance. Such linker-hinge interface domains covalently join two molecules, maintain the biological activities of linked molecules (target binding), stabilize the biological characteristics of new molecule (solubility and 4° C. stability), maintain the chemical, biochemical and physical properties (cytotoxicity) of the linked molecules, and modulate the biological characteristics of the linked molecules (activating T-lymphocytes without significant sign of proliferations). Both linker (GGGGS) and hinge (CPPCP) sequences are required to establish functional linker-hinge interface domains as deletion of any of the component resulted in significant lost of T-lymphocyte mediated activity.


Find Patent Forward Citations

Loading…